Myocardial Infarction News and Research

RSS

Remote exercise-based cardiac rehabilitation can be an additional option for heart patients

Remotely delivered exercise-based cardiac rehabilitation, when added to center-based programs, resulted in a similar number of completed sessions as center-based programs only, according to results presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Rapid pathway for diagnosing heart attacks does not improve emergency discharge rates

A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither reduced the length of time patients spent in the ED nor increased direct discharge from the ED.

29 Aug 2026

Functional angiography outperforms conventional imaging in AIR-STEMI trial

Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.

29 Aug 2026

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Trial shows antiplatelet therapy needs personalization after stent implantation

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.

29 Aug 2026

Milvexian fails to reduce cardiovascular events after acute coronary syndrome

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.

29 Aug 2026

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

29 Aug 2026

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.

29 Aug 2026

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Immediate evolocumab use after heart attack improves cholesterol goals but not survival

Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not observed compared with standard care.

29 Aug 2026

New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage

Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had had an intracranial hemorrhage, according to results presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Major cardiac societies develop and publish a universal definition of myocardial infarction

When a myocardial infarction, such as a heart attack, occurs, being able to classify its type can improve diagnosis and treatment.

28 Aug 2026

Missing doses of antihypertensive medication erase life-saving cardiovascular benefits

The true impact of missing doses of blood pressure-lowering medication will be demonstrated in a presentation at ESC Congress 2026.

27 Aug 2026

Artificial sweetener xylitol associated with higher risk of adverse cardiovascular events

A study to be presented at ESC Congress 2026 will show that high blood levels of the artificial sweetener, xylitol, were associated with increased risk of major adverse cardiovascular events.

26 Aug 2026

Study links finasteride to fewer complications after heart attack in men

Patients treated with medication for benign prostatic hyperplasia at the time of a severe acute heart attack experienced fewer serious complications from the attack, according to a study from the University of Gothenburg.

26 Aug 2026

What decades of wine research can, and cannot, tell us about health

A narrative review found that moderate wine intake has repeatedly been associated with lower all-cause and cardiovascular mortality, with proposed mechanisms involving ethanol and grape-derived polyphenols, but the evidence remains largely observational and cannot establish causation. The authors argue that drinking pattern, beverage type, age, cancer risk, and risk-modeling choices all influence how the J-shaped association should be interpreted and how alcohol guidelines are developed.

25 Aug 2026

Could a daily vinegar drink help with constipation? A small trial offers a clue

A randomized, double-blind trial found that adults with mild constipation who drank a vinegar beverage daily for four weeks had more frequent bowel movements than those receiving placebo. Exploratory findings also suggested earlier improvements in bowel habits, although the small feasibility-based trial requires confirmation in larger and more diverse populations.

24 Aug 2026

Semaglutide’s heart benefits may partly involve reduced inflammation

A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.

24 Aug 2026

Only three of 1,357 FDA-cleared AI devices tested patient outcomes

Researchers found that among 1,357 FDA-cleared or approved AI/ML-enabled medical devices, only 34 were linked to registered clinical trials and just three had been evaluated for patient-centered outcomes. The study highlights major gaps in prospective testing, demographic representation, transparency, and evidence showing whether medical AI meaningfully improves patients’ health.

20 Aug 2026

What 3,600 adults with diabetes revealed about lifestyle and heart health

In 3,612 British adults with type 2 diabetes, greater adherence to the Mediterranean Lifestyle Index was associated with lower risks of major adverse cardiovascular events, cardiovascular death, and all-cause mortality over more than a decade of follow-up. Dietary patterns, physical activity, rest, and social habits all contributed to the observed associations, although the observational study cannot establish causality.

19 Aug 2026

Myocardial Infarction News and Research

Remote exercise-based cardiac rehabilitation can be an additional option for heart patients

Rapid pathway for diagnosing heart attacks does not improve emergency discharge rates

Functional angiography outperforms conventional imaging in AIR-STEMI trial

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Trial shows antiplatelet therapy needs personalization after stent implantation

Milvexian fails to reduce cardiovascular events after acute coronary syndrome

Trial findings do not support prasugrel monotherapy at the time of primary PCI for STEMI patients

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

Immediate evolocumab use after heart attack improves cholesterol goals but not survival

New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage

Major cardiac societies develop and publish a universal definition of myocardial infarction

Missing doses of antihypertensive medication erase life-saving cardiovascular benefits

Artificial sweetener xylitol associated with higher risk of adverse cardiovascular events

Study links finasteride to fewer complications after heart attack in men

What decades of wine research can, and cannot, tell us about health

Could a daily vinegar drink help with constipation? A small trial offers a clue

Semaglutide’s heart benefits may partly involve reduced inflammation

Only three of 1,357 FDA-cleared AI devices tested patient outcomes

What 3,600 adults with diabetes revealed about lifestyle and heart health

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News